pharmaceuticals
A new German-Lithuanian collaboration is breaking ground in space health research. Delta Biosciences’ mission to the International Space Station, in partnership with ESA, involves key German research institutes like GSI and DLR. Their joint goal: to explore radioprotective measures that benefit both astronauts and patients on Earth. The project marks a significant step forward in European...
Roche achieved solid sales growth in the first three quarters of 2025. This result was driven by strong demand for novel medicines and diagnostics, as well as a robust pipeline. The company is raising its profit forecast and showing progress with numerous new drugs for the treatment of serious diseases such as Alzheimer's, hemophilia, cancer, and obesity.
Merck is pursuing a focused growth strategy across Life Science, Healthcare, and Electronics. Through targeted acquisitions, investments, and customer-centric business models, the company is expanding its presence in dynamic technology markets. Discover how Merck leverages innovation in rare diseases, semiconductor materials, and digital platforms and what underpins its stable outlook for 2025.
With its new Launch and Technology Center in Darmstadt in Germany, Merck has invested €160 million in the future of drug development. The facility combines research and commercial production to make small molecule therapies available more quickly. Modern technology, sustainable construction, and flexible production environments are designed not only to strengthen the company's competitiveness, but...
In the pharmaceutical industry, extreme accuracy is essential – especially in the production of inhalers, dispensers, and pens. At its Neuenburg site, Nemera relies on Mitutoyo measurement technology to guarantee precise drug delivery. From coordinate measuring machines and optical systems to advanced CT solutions, this partnership drives innovation and sets new quality benchmarks in medical...
Sandoz has announced another step in its sustainability strategy, focusing on solar energy from Spain. Together with Elawan Energy, new plants will be built to cover a significant portion of the electricity needs of European sites from renewable sources. The partnership is part of a long-term plan to significantly reduce the company's environmental footprint.
Merck generated revenue of €5.26 billion in the second quarter of 2025. Life Science and Healthcare drove growth, while the acquisition of Springworks strengthened the oncology portfolio. Despite negative currency effects, the company raised its forecast for the full year. “We achieved solid organic sales and earnings growth,” emphasized Belén Garijo, Chair of the Executive Board and CEO of Merck.
Siemens has completed the acquisition of Dotmatics, a US provider of R&D software for the life sciences industry. The company is valued at $5.1 billion. With its integration into Siemens Digital Industries Software, the company is expanding its product lifecycle management (PLM) portfolio to include research and development as well as production.
Roche plans to invest $50 billion in the US over the next five years. These investments will strengthen the pharmaceutical company's presence in the United States, where it has 13 manufacturing sites and 15 research and development sites for pharmaceuticals and diagnostics. More than 12,000 new jobs are expected to be created, including nearly 6,500 in construction and 1,000 in new and expanded...
Due to the strong demand for new medicines and diagnostics, Roche increased its sales by three percent to CHF 60.5 billion in 2014. In the previous year, sales amounted to CHF 58.7 billion. Adjusted for currency effects, sales even rose by seven percent. Core operating profit rose by eight percent as a result of higher sales, an improved gross profit margin and efficient cost management. CEO...
